SCHEMBL5719260

SCHEMBL5719260

CC(=O)Nn1c(=O)n(C)c(=O)c2c1nc(N1CCN(C(=O)OC(C)(C)C)CC1)n2-c1ccccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.41
CNR2 P34972 2/20 0.41
MAPT P10636 3/20 0.39
MAPK8 P45983 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 1/20 0.38
CCNK O75909 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCND3 P30281 1/20 0.38
CDK9 P50750 1/20 0.38
CDK6 Q00534 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OGFRL1 Q5TC84 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5719246 0.89 L3MBTL1 (0.45) CNR1CNR2MAPTL3MBTL1GAA
SCHEMBL5719230 0.85 CNR1 (0.41) CNR1CNR2MAPTMAPK8L3MBTL1
SCHEMBL5718793 0.84 MEN1 (0.42) CNR1CNR2MAPTMAPK8L3MBTL1
SCHEMBL5719021 0.84 L3MBTL1 (0.42) CNR1CNR2MAPTL3MBTL1GAA
SCHEMBL5719233 0.83 L3MBTL1 (0.41) CNR1CNR2MAPTMAPK8L3MBTL1
SCHEMBL5719186 0.83 L3MBTL1 (0.44) CNR1CNR2MAPTL3MBTL1GAA
SCHEMBL2952792 0.82 L3MBTL1 (0.42) CNR1CNR2MAPTMAPK8L3MBTL1
SCHEMBL2954897 0.81 GAA (0.44) CNR1CNR2MAPTMAPK8L3MBTL1
SCHEMBL2957100 0.81 CNR1 (0.43) CNR1CNR2MAPTMAPK8L3MBTL1
SCHEMBL5719184 0.79 L3MBTL1 (0.58) CNR1CNR2MAPTL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074798-B2 Xanthine derivative and DPPIV inhibitor EISAI CO., LTD (JP) 2006-07-11 US disclosed
EP-1338595-B1 Xanthine derivatives as DPP-IV inhibitors EISAI CO LTD (JP) 2006-05-03 EP disclosed
US-20040082570-A1 Xanthine derivative and DPPIV inhibitor EISAI CO., LTD. (JP) 2004-04-29 US disclosed
EP-1338595-A2 Xanthine derivatives as DPP-IV inhibitors Eisai Co., Ltd. (JP) 2003-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082570-A1 Xanthine derivative and DPPIV inhibitor DPP4, DPP9, DPP7 CNR1 1472/4885CNR2 2504/4885MAPT 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.